734 related articles for article (PubMed ID: 15742545)
1. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
[TBL] [Abstract][Full Text] [Related]
2. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
[TBL] [Abstract][Full Text] [Related]
3. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
Debess J; Riis JØ; Engebjerg MC; Ewertz M
Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
[TBL] [Abstract][Full Text] [Related]
5. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impairment associated with adjuvant therapy in breast cancer.
Bender CM; Sereika SM; Berga SL; Vogel VG; Brufsky AM; Paraska KK; Ryan CM
Psychooncology; 2006 May; 15(5):422-30. PubMed ID: 16097037
[TBL] [Abstract][Full Text] [Related]
7. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study.
Tager FA; McKinley PS; Schnabel FR; El-Tamer M; Cheung YK; Fang Y; Golden CR; Frosch ME; Habif U; Mulligan MM; Chen IS; Hershman DL
Breast Cancer Res Treat; 2010 Aug; 123(1):25-34. PubMed ID: 19894112
[TBL] [Abstract][Full Text] [Related]
8. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
[TBL] [Abstract][Full Text] [Related]
9. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy.
Silverman DH; Dy CJ; Castellon SA; Lai J; Pio BS; Abraham L; Waddell K; Petersen L; Phelps ME; Ganz PA
Breast Cancer Res Treat; 2007 Jul; 103(3):303-11. PubMed ID: 17009108
[TBL] [Abstract][Full Text] [Related]
10. Analysis of memory deficits following chemotherapy in breast cancer survivors: evidence from the doors and people test.
Prokasheva S; Faran Y; Cwikel J; Geffen DB
J Psychosoc Oncol; 2011; 29(5):499-514. PubMed ID: 21882931
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; van Dam FS
Breast Cancer Res Treat; 2005 Nov; 94(1):53-61. PubMed ID: 16175317
[TBL] [Abstract][Full Text] [Related]
12. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.
Falleti MG; Sanfilippo A; Maruff P; Weih L; Phillips KA
Brain Cogn; 2005 Oct; 59(1):60-70. PubMed ID: 15975700
[TBL] [Abstract][Full Text] [Related]
13. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
14. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study.
Quesnel C; Savard J; Ivers H
Breast Cancer Res Treat; 2009 Jul; 116(1):113-23. PubMed ID: 18629633
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
17. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
Fan HG; Houédé-Tchen N; Yi QL; Chemerynsky I; Downie FP; Sabate K; Tannock IF
J Clin Oncol; 2005 Nov; 23(31):8025-32. PubMed ID: 16258100
[TBL] [Abstract][Full Text] [Related]
18. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
[TBL] [Abstract][Full Text] [Related]
19. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy.
Ahles TA; Saykin AJ; Noll WW; Furstenberg CT; Guerin S; Cole B; Mott LA
Psychooncology; 2003 Sep; 12(6):612-9. PubMed ID: 12923801
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and adjuvant tamoxifen treatment in breast cancer patients.
Boehm DU; Lebrecht A; Eckhardt T; Albrich S; Schmidt M; Siggelkow W; Kandelhardt E; Koelbl H
Eur J Cancer Care (Engl); 2009 Sep; 18(5):500-6. PubMed ID: 19490009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
